Forty Seven Inc

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a ''don't eat me'' signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.

Word of the biotech's pending acquisition pushed its stock to a record high.

Why Forty Seven Stock Skyrocketed 64.5% in March

The immuno-oncology buyout is set to close this quarter.

Should You Buy Forty Seven Before Gilead Sciences' Acquisition Closes?

Grocery Outlet

Trillium Therapeutics

Despite the lagging markets, companies that offer pharmaceuticals and FMCG products have witnessed a surge in recent weeks, largely driven by strong demand for their goods.

Demand for Essential Goods Rises Amid Coronavirus: 3 Winners

Take advantage of a declining stock price for this soon-to-be-acquired company.

1 Safe-Haven Stock for the Near Term

ARK Genomic Revolution Multi-Sector ETF

Aytu BioScience

VanEck Vectors Biotech ETF

Loncar Cancer Immunotherapy ETF

Co-Diagnostics

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Vir Biotechnology

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Coronavirus Scare Supports These Biotech ETFs & Stocks

MENLO PARK, Calif. and NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with Rocket’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy, RP-L102. The initial collaboration will evaluate this treatment regimen in Fanconi Anemia (FA), a genetic disease that affects patients’ capacity to produce blood cells and is associated with an increased risk of leukemia and other neoplasms. RP-L102, Rocket’s gene therapy approach for FA, involves treatment with patients’ own gene-corrected blood forming stem cells (hematopoietic stem cells, or HSCs).

Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

Gilead Sciences

Gilead: COVID-19 And Forty Seven Add To Intrigue Of A Company In Transition

Gilead Sciences' Acquisition Of Forty Seven Was A Wise Move, CD47 Space Is Key Future Cancer Target

Gilead Sciences is attempting to alter its fortunes through the acquisition of immuno-oncology outlet Forty Seven. Gilead will pay $4.9 billion to acquire Forty Seven.

Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?

The cancer treatment specialist found a buyer for its business.

Why Forty Seven Stock Soared 57% in February

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

Gilead Sciences Inc  said on Monday it would buy Forty Seven Inc  for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.

Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline

Gilead Sciences will buy cancer-focused player Forty Seven for $4.9 billion, the biotech company said Monday — sending FTSV stock rocketing. Gilead will pay $95.50 per share of FTSV stock.

Gilead Confirms $4.9 Billion Takeover To Bolster Cancer Pipeline

The deal will enable Gilead to scoop up promising blood cancer drug magrolimab.

Gilead Sciences Acquiring Cancer-Focused Biotech Forty Seven for $4.9 Billion

Forty Seven Inc. (NASDAQ: FTSV) shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences Inc.

Is Gilead Overpaying for Forty Seven?

Gilead Sciences and Forty Seven are reportedly tying the knot through a $4.9 billion buyout agreement. Shares of Trillium Therapeutics, a fellow CD47 drugmaker, are also jumping on this news.

Why Gilead Sciences, Forty Seven, and Trillium Therapeutics Are Moving Higher Today

Forty Seven Inc (NASDAQ: FTSV) shares were skyrocketing Monday morning, adding on to the roughly 19% gain the stock made Friday, after Gilead Sciences, Inc.

Gilead Confirms Deal To Buy Biotech Forty Seven For $4.9B

Shares of Forty Seven Inc. FTSV, +18.88% shot up 61% in premarket trading Monday, after the immuno-oncology company agreed to be acquired by Gilead Sciences Inc.

Forty Seven's stock rockets Gilead's $4.9 billion buyout deal

Forty Seven shares soared on the rumor, but Gilead's stock price fell.

Gilead Reportedly in Talks to Acquire Cancer Biotech Forty Seven

Shares of thinly-traded cancer biotech Forty Seven Inc (NASDAQ: FTSV) are advancing Friday on reports of a takeover interest.

Gilead Eyes Takeover Of Cancer Biotech Forty Seven: Report

Shares of cancer-therapy company Forty Seven Inc. FTSV, +1.01% shot up more than 30% in after-hours trading Thursday after a report that Gilead Sciences Inc.

Biotech company Forty Seven surges 30% after hours on report of Gilead interest

Positive data from a recent study on its lead compound signifies a turning point for the company and could provide further value for investors.

This Cancer Drug Is Driving Forty Seven's Stock Higher

Forty Seven intends to initiate the pivotal phase 3 ENHANCE study exploring magrolimab in combination with azacitidine versus azacitidine alone by Q2 of 2020.

Forty Seven Validates CD47 With 'Don't Eat Me' Tech, Pivotal Studies To Be Initiated In 2020

Today, AER trades at $60/share whilst shareholders' equity as at end'19 on my numbers is around $71.5/share - so call is 0.84x P/B.

Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 --  -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk MDS and AML Expected Mid-Year 2020 -- -- Initial Data from Phase 3 Trial in DLBCL Expected in 4Q 2020 --   -- FSI-174 and FSI-189 Expected to Enter Phase 1 in 1Q and 2Q 2020, Respectively --   -- FDA Granted Orphan Drug Designation for Magrolimab in MDS --  MENLO PARK, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today outlined its strategic plan and expected milestones for 2020.

News for Forty Seven Inc Stock (FTSV)